Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Indivior Pharmaceuticals (INDV) Operating Expenses (2024 - 2025)

Indivior Pharmaceuticals (INDV) has 2 years of Operating Expenses data on record, last reported at -$487.0 million in Q4 2025.

  • For Q4 2025, Operating Expenses fell 337.56% year-over-year to -$487.0 million; the TTM value through Dec 2025 reached $34.0 million, down 96.3%, while the annual FY2025 figure was $34.0 million, 96.3% down from the prior year.
  • Operating Expenses reached -$487.0 million in Q4 2025 per INDV's latest filing, down from $187.0 million in the prior quarter.
  • Across five years, Operating Expenses topped out at $338.0 million in Q2 2024 and bottomed at -$487.0 million in Q4 2025.